slideshow 1 slideshow 2 slideshow 3


The story on REGENER-AR project has been published on Horizon 2020 website

Find it HERE on H2020 website.

Toll-like receptors as modulators of mesenchymal stem cells

Olga DelaRosa, Wilfried Dalemans and Eleuterio Lombardo
Research and Development Department, TiGenix SA, Parque Tecnológico de Madrid, Madrid, Spain.


The REGENER_AR Newsletter provides the scientific community with organisational updates and project announcements.

REGENER-AR (Bringing Regenerative Medicine into the market: Allogeneic eASCs Phase IB/IIA clinical trial for treating Rheumatoid Arthritis) is a clinical translational collaborative project which aims at developing a broadly available and clinically applicable treatment for Rheumatoid Arthritis (RA) by exploiting the biology of living human expanded allogeneic mesenchymal adult stem cells extracted form adipose tissue (eASCs).

To accomplish this goal we will test advanced cellular therapy through a phase Ib/IIb clinical trial in order to define the safety and feasibility of the systemic administration of allogeneic eASCs in patients with RA. We will also advance in the difficulties and barriers that prevent cell therapy to become a largely available product in the market by facing several issues related to the production scale-up, effective clinical treatment and regulatory affairs compliance.

General Information

Project start date: 1st January 2012
Project duration: 36 months
Contract no: 279174 EC Funding: 5,925,461.50 €
Funding scheme: Collaborative Project (small or medium-scale focused research project).
Research topic: HEALTH.2011.1.4-1: Regenerative medicine clinical trials (FP7-HEALTH-2011-two-stage).

This project has received funding from the European Union's Seventh Programme for research, technological development and demonstration under grant agreement No 279174.